Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436276 · ClinicalTrials.gov registry record · Phase 1
A Study of Ad26.COV2.S in Adults (COVID-19)
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 1,085
- Enrollment target
NCT04436276 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 1,085 participants.
The verdict
NCT04436276, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,085 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort in healthy adults aged greater than or equal to (\>=) 18 to less than or equal to (\<=) 55 years and in adults aged \>= 65 years in good health with or without stable underlying conditions. The purpose of the study is also to assess the safety and reactogenicity of Ad26.COV2.S administered as ad hoc booster vaccination in healthy adults aged \>= 18 to \<= 55 years and in adults \>= 65 years in good health with or without stable underlying conditions.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,085 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04436276
The ClinicalTrials.gov registry entry for NCT04436276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,085 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04436276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04436276 about?
NCT04436276 is a clinical study titled "A Study of Ad26.COV2.S in Adults (COVID-19)". The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination administered in one cohort in healthy adults aged greater than or equal to (\...
What is the current status of trial NCT04436276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,085 participants. The study started on 2020-07-15. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT04436276?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04436276?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.